Development of Magnetic-Resonance Contrast Composition Based on Disodium Salt of Gd-DTPA

Abstract:

In this research we have studied contrast composition in the form of an aqueous solution containing gadolinium oxide (Gd₂O₃), diethylenetriaminepentaacetic acid (DTPA), medical polymer - polyvinylpyrrolidone mol. sq. (12000 ± 5000) daltons in an amount of 0.5-5 wt. %. To reduce the content of free gadolinium in the composition it has been suggested to change the stoichiometric ratio of the concentrations of DTPA/Gd₂O₃ in the mixture. The studies have shown that at a concentration ratio of DTPA/Gd₂O₃, 2.07 - 2.10 the impurity content of free gadolinium is at least 0.25%, which is significantly below the regulated value - 0.5%. The conducted biomedical tests have confirmed the functionality of the resulting contrast composition.

• Periodical: Advanced Materials Research (Volume 1084)
• Pages: 549-553
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.1084.549
• Online since: January 2015
• Authors: Viktor S. Skuridin, Elena S. Stasyuk, Vladimir I. Chernov
• Keywords: Gadolinium, Magnetic Resonance Contrast

References

[1] A.N. Konovalov, V.N. Kornienko, I.N. Pronin, Magnitno-rezonansnaya tomografiya v neirokhirurgii (Magnetic resonance imaging in neurosurgery), Kondor-M, Moscow, (1997).

[2] P.A. Rink, Magnitnyi rezonans v meditsine (Magnetic resonance in medicine), GEOTAR-Med, Moscow, (2003).

[3] L.A. Tyutin, E.A. Rokhlin, G.D. Dyski, Y.I. Neronov, Ispol'zovanie magnitnorezonansnoi tomografii v izuchenii tsentral'noi nervnoi sistemy, Morfologiya 106(4) (1994) 165—168.

[4] M.G. Yakobson, A.V. Podoplelov, S.B. Rudykh, Vvedenie v MR-tomografiyu, Siberian Department of Russian Academy of Medical Science, Novosibirsk, (1991).

[5] L.A. Tyutin, A.F. Panfilenko, N.V. Arzumanova, Magnitno-rezonansnaya tomografiya s ispol'zovaniem kontrastnogo preparata Magnevist, Vestnik rentgenologii i radiologii, 2 (1996) 6-12.

[6] K.N. Sorokina, A.A. Tulupov, T.G. Tolstikova, V.Y. Usov, Sovremennye podkhody k sozdaniyu kontrastnykh preparatov dlya magnitno-reznansnoi tomograficheskoi diagnostiki, Byulleten' sibirskoi meditsiny, 6 (2011) 79-86.

[7] P. Arvella, A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters, J. Prog. Pharmacol, 2 (1979) 69-112.

[8] D.D. Stark, W.G. Bradley, Magnetic resonance imaging, The C. V. Mosby Company: St. Louis, Washington D.C., Toronto, 1988, pp.161-181.

[9] Savin S.B., Sh. Arsenazo, Atomizdat (Atomic Publ. ), Moscow, (1966).

[10] H. Gries, D. Rosenberg, H. Weinmann, DE Patent 3129906, МКI А 61 (1981).

[11] V.N. Kulakov, V.F. Khokhlov, Y.V. Gol'tyapin, S.M. Nikitin, P.V. Sergeev, RU Patent №2150961 (2000).

[12] Y.B. Lishmanov, V.I. Chernov, V.A. Zuev, G.I. Volkova, RU Patent №2308290 (2007).